ESMO 2019 Prostate Cancer - Results from #40

Viewing 41-60 of 63 articles

ESMO 2019: Invited Discussant: (LBA50, 845PD, 846PD and 847PD)Phase 2 Study GALAHAD, CDK12-altered Prostate Cancer, Preliminary results from the TRITON2 study, and HRRm in Tumor Tissue from men with mCRPC Screened for the PROfound Study

ESMO 2019: CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, PARP and PD1 Inhibitors

ESMO 2019: Pre-Specified Interim Analysis of GALAHAD: A Phase 2 Study of Niraparib in Patients with mCRPC and Biallelic DNA-Repair Gene Defects

ESMO 2019: CCTG IND 232 - Phase II Study of Durvalumab with or without Tremelimumab in Patients with mCRPC

ESMO 2019: GALAHAD - A Phase 2 Study of Niraparib in Patients with mCRPC and Biallelic DNA-Repair Gene Defects, A Pre-Specified Interim Analysis

ESMO 2019: CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, PARP inhibitors, and PD1 inhibitors

ESMO 2019: Invited Discussant: The International Germ Cell Cancer Collaborative Group Update

Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019

ESMO 2019: Redefining the International Germ Cell Cancer Collaborative Group Classification in Advanced Non-Seminoma

ESMO 2019: Docetaxel for Hormone-Naïve Prostate Cancer: Results from Long-Term Follow-Up of Metastatic (M1) Patients in the STAMPEDE Randomized Trial and Sub Group Analysis by Metastatic Burden - Medical Oncologist Perspective

ESMO 2019: Adjuvant or Salvage Radiotherapy for the Treatment of Localized Prostate Cancer? A Prospectively Planned Aggregate Data Meta-Analysis - A Medical Oncologist's Perspective

ESMO 2019: Timing of Radiotherapy after Radical Prostatectomy: First Results from the RADICALS Radiation Therapy Randomised Controlled Trial

ESMO 2019: Invited Discussant - An Update on the Phase 3 SPARTAN Study and Long-term Outcomes for M1 Patients in the STAMPEDE Randomized Trial - A Medical Oncologist's Perspective

ESMO 2019: Invited Discussant - An Update on the Phase 3 SPARTAN Study and Long-term Outcomes for M1 Patients in the STAMPEDE Randomized Trial

ESMO 2019: Apalutamide and Overall Survival in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Updated Results From the Phase 3 SPARTAN Study

ESMO 2019: RADICALS and ARTISTIC Discussion: Thoughts from a Radiation Oncologist

ESMO 2019: Timing of Radiotherapy After Radical Prostatectomy: First Results from the RADICALS Radiotherapy Randomized Controlled Trial

ESMO 2019: Treatment Intensification in Advanced Prostate Cancer: SPARTAN, STAMPEDE, and Others

ESMO 2019: Adjuvant or Salvage Radiotherapy for the Treatment of Localized Prostate Cancer? A Prospectively Planned Aggregate Data Meta-analysis

ESMO 2019: Docetaxel for Hormone-naïve Prostate Cancer: Results from Long-term Follow-up of Metastatic Patients in the STAMPEDE Randomized Trial and Sub-group Analysis by Metastatic Burden

1
2
3
4